With a newly minted approval in hand for Qsymia, Vivus is ready to start the battle for top obesity drug with Arena's Belviq. Will Vivus' likely first-to-market status help, or will Belviq have the upper hand because of Qsymia's labeling? Watch and find out what it all means for investors.

David Williamson holds no position in any company mentioned. Check out his holdings and a short bio.
We Fools don't all hold the same opinions, but we all believe that
considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.